CSIR - Institute of Genomics and Integrative Biology, New Delhi 110025, India.
CSIR - Institute of Genomics and Integrative Biology, New Delhi 110025, India.
Cytokine. 2019 Oct;122:154190. doi: 10.1016/j.cyto.2017.10.012. Epub 2017 Nov 1.
Colony stimulating factors (CSFs) play a central role in the development and functional maturation of immune cells besides having pleiotropic effects on cells of the vascular wall. The production of CSFs is induced by multiple atherogenic and inflammatory stimuli and their expression levels are often correlated positively with advanced atherosclerotic plaques and adverse cardiovascular events in humans suggesting that CSFs play a critical role in the pathophysiology of atherosclerosis progression. Interestingly, recombinant CSFs as well as anti-CSFs are being increasingly used for diverse clinical indications. However, the effect of these novel therapeutics on atherosclerotic plaque progression is not well understood. Herein, we summarize the currently available literature on the complex role of CSFs in various stages of atherosclerosis and emphasize the necessity for conducting further mechanistic studies in animal models of atherosclerosis as well as the need for evaluating the cardiovascular safety of CSF-based therapies in humans.
集落刺激因子(CSFs)除了对血管壁细胞具有多效性作用外,在免疫细胞的发育和功能成熟中也起着核心作用。CSFs 的产生受到多种动脉粥样硬化和炎症刺激的诱导,其表达水平通常与人类的晚期动脉粥样硬化斑块和不良心血管事件呈正相关,这表明 CSFs 在动脉粥样硬化进展的病理生理学中起着关键作用。有趣的是,重组 CSFs 以及抗 CSFs 越来越多地用于多种临床适应症。然而,这些新型治疗药物对动脉粥样硬化斑块进展的影响尚不清楚。本文总结了目前关于 CSFs 在动脉粥样硬化各个阶段的复杂作用的文献,并强调了在动脉粥样硬化动物模型中进行进一步的机制研究的必要性,以及在人类中评估基于 CSF 的治疗方法的心血管安全性的必要性。